Astaxanthin
Astaxanthin, marine carotenoid
Written by Aaron CuhaReviewed Sep 2026
Also known as: Haematococcus pluvialis extract, Asta
It extended male mouse lifespan once, then showed no benefit when the same programme retested it at a different dose. In females, pooled across sites, it was associated with shorter lifespan.
Overview
Astaxanthin is the clearest single illustration on this site of why a lifespan result is a property of a dose rather than of a compound.
In the 2024 Interventions Testing Program cohort it extended lifespan in male mice. The 90th percentile lifespan rose by 6 percent in absolute terms, though that was not significant by the formal maximal lifespan test. A real positive, published.
The same programme then retested it at a different dose and starting age in the 2026 cohort and found no benefit at all. In females, pooling all three sites, astaxanthin was among the compounds associated with significantly reduced lifespan, though a reanalysis excluding one site with unusually long-lived control females removed that specific finding for astaxanthin while leaving it for two other compounds.
So the same compound, in the same programme, in the same strain: positive once, null on retest, and a female signal that appeared and then partly dissolved on closer analysis. There is a disclosed conflict worth knowing in the 2024 paper: two authors run the company that supplies the astaxanthin used.
Mechanism of action
A xanthophyll carotenoid from the microalga Haematococcus pluvialis, responsible for the pink colour of salmon and flamingos. Its polar end groups let it span the cell membrane rather than sitting within the lipid core as beta-carotene does, which is the structural basis of the claim that it protects membranes more effectively. It quenches singlet oxygen and scavenges free radicals, and unlike some carotenoids it is not converted to vitamin A. Note that a purely antioxidant mechanism sits poorly with the lifespan literature, where antioxidant supplementation has repeatedly failed to extend life and occasionally shortened it.
Human evidence
Widely sold with a substantial human literature on markers and short-term outcomes, and nothing at all on lifespan or healthspan.
- No human trial has examined lifespan, healthspan or any ageing endpoint.
- The lifespan evidence is two mouse cohorts from the same programme that disagree with each other.
- It is well tolerated at supplement doses, with skin pigmentation the most notable effect at higher intakes.
- Absorption depends substantially on being taken with dietary fat.
What this does not tell you: The two mouse results are the whole ageing case and they contradict each other, which is the most informative thing about this compound. The positive carries a disclosed commercial conflict, the retest was conducted by the same programme at a different dose and starting age and found nothing, and a female harm signal appeared in the pooled analysis before partly dissolving on site-specific reanalysis. None of that is a scandal. It is what careful testing looks like, and it means the honest answer about astaxanthin and lifespan is that nobody knows.
Reading the research record
The 2026 cohort did something unusual and valuable: it retested compounds the same programme had already found to extend lifespan, at different doses or from later starting ages. Astaxanthin, mitoglitazone and meclizine all showed no benefit the second time. In females, pooling all three sites, astaxanthin, late-start mitoglitazone and pioglitazone were associated with significantly reduced lifespan; a site-specific reanalysis found unusually long-lived control females at one site, and excluding it left the negative effect for mitoglitazone and pioglitazone only. The authors' own conclusion is that timing and dosage are critical variables and that single-site or single-cohort findings require cautious interpretation.
Astaxanthin is the compound to point at when someone says a supplement extends lifespan in mice. It did, once, in males, at one dose, from one starting age, in a study where two authors ran the supplying company. The same programme retested it and found nothing. That is not a story about fraud or about a bad supplement; it is a story about how fragile a single lifespan result is, and about why the retest cohort was the most valuable thing this programme published in years.
The Interventions Testing Program is run by the National Institute on Aging at three independent sites, using UM-HET3 mice, a genetically heterogeneous four-way cross, so a result cannot be an artefact of one inbred strain. Both sexes are tested, cohorts are large enough to detect roughly a 10 percent change in lifespan, and nulls are published alongside positives. Nothing else in ageing research has that combination, which is why its results carry more weight than a single-laboratory finding and why its failures to replicate are worth as much attention as its successes.
The evidence, charted
Fig. 1 · evidence composition
0of 2 citations (0%) are in people
Every citation cited here is Animal work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2024 and 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2024
Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not
The positive. Astaxanthin extended lifespan in male mice, started at 12 months of age. The 90th percentile lifespan was extended in absolute value by 6 percent in males, though not significantly by the Wang-Allison test. Late-life weights were lower in females fed astaxanthin without a significant lifespan effect in them. Disclosed conflict: two authors run the company that supplies the astaxanthin used in the study.
GeroScience - Animal2026
Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan
The retest. Astaxanthin showed no lifespan benefit when administered at a different dose or starting at a later age. In females, pooling all three sites, astaxanthin was associated with significantly reduced lifespan; site-specific reanalysis excluding one site with unusually long-lived control females left a negative effect only for mitoglitazone and pioglitazone. The authors conclude that timing and dosage are critical variables.
GeroScience
Frequently asked questions
Does astaxanthin extend lifespan?
It did in male mice in one cohort, at one dose. The same testing programme retested it at a different dose and later starting age and found no benefit. There is no human lifespan data. The honest answer is that nobody knows.
Was the positive result compromised?
It was disclosed rather than hidden: two authors of that paper run the company supplying the astaxanthin used. That is not disqualifying and it is a reason to weight the independent retest, which found nothing, at least as heavily as the original.
Is it harmful in females?
The pooled analysis across all three sites associated it with significantly reduced female lifespan. A site-specific reanalysis found unusually long-lived control females at one site, and excluding that site removed the effect for astaxanthin while leaving it for two other compounds. So the signal is uncertain rather than established, and it is a reason for caution rather than alarm.
Is it worth taking at all?
For ageing there is no support. It is well tolerated, it needs dietary fat for absorption, and its wider human literature concerns markers and short-term outcomes rather than anything about lifespan.